Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jul;28(7):579, 584-5.

Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis

Marni B Siegel, Amanda E D Van Swearingen, Carey K Anders
Comment

Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis

Marni B Siegel et al. Oncology (Williston Park). 2014 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Lim E, Lin NU. New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park) 2012;26:652–9. - PubMed
    1. Anders CK, Deal AM, Dees EC, et al. LCCC 1025: a phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. J Clin Oncol. 2012;30(suppl) abstr TPS656. - PMC - PubMed
    1. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases. American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 May 5; [Epub before print] - PMC - PubMed
    1. Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013;14:e396–406. - PubMed
    1. Lim E, Lin NU. Updates on the management of breast cancer brain metastases. Oncology (Williston Park) 2014;28:XXX–XXX. - PubMed

MeSH terms